Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 14/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7845115 | 0.66 | NOS2 (0.43) | TLR8TLR7 | |
| SCHEMBL16660697 | 0.61 | MAPT (0.41) | TLR8 | |
| SCHEMBL15232742 | 0.61 | PDE10A (0.39) | TLR7 | |
| SCHEMBL19354268 | 0.61 | ADORA2A (0.34) | XDH | |
| SCHEMBL31060074 | 0.60 | RARB (0.48) | — | |
| SCHEMBL4988562 | 0.60 | TLR8 (0.37) | TLR8TLR7 | |
| SCHEMBL2364312 | 0.60 | KCNH2 (0.40) | — | |
| SCHEMBL31667844 | 0.59 | MAPT (0.43) | — | |
| SCHEMBL16650646 | 0.59 | MAPT (0.43) | — | |
| SCHEMBL24618337 | 0.59 | KDM4E (0.38) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570143-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2020-02-25 | — | — | US | disclosed |
| US-20190040074-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2019-02-07 | — | — | US | disclosed |
| EP-2920181-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIV HEALTH NETWORK (CA) | 2019-01-09 | — | — | EP | disclosed |
| US-10106545-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2018-10-23 | — | — | US | disclosed |
| US-20170217966-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9573954-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-21 | — | — | US | disclosed |
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2015-10-22 | — | — | US | disclosed |
| EP-2920181-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | University Health Network (UHN) (CA) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014075168-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2014-05-22 | — | — | WO | disclosed |
| US-20110206661-A1 | TRIMETHOXYPHENYL INHIBITORS OF TYROSINE KINASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | TLR8 3577/4885ABL1 696/4885SRC 2195/4885 |
| US-20110206661-A1 | TRIMETHOXYPHENYL INHIBITORS OF TYROSINE KINASE | ABL1, LCK, SRC | TLR8 2645/4885ABL1 1/4885SRC 3/4885 |
| US-10570143-B2 | Pyrazolopyrimidine compounds | CYP3A5, CYP3A7, DPYD | TLR8 3577/4885ABL1 696/4885SRC 2195/4885 |
| US-10106545-B2 | Pyrazolopyrimidine compounds | CYP3A5, CYP3A7, DPYD | TLR8 3209/4885ABL1 635/4885SRC 2650/4885 |
| US-20170217966-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | TLR8 3209/4885ABL1 635/4885SRC 2650/4885 |
| US-20190040074-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | TLR8 3209/4885ABL1 635/4885SRC 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.